DFDA

Papaverine (Intra-arterial)

Treatment for Vascular Intestinal Disorders

Typical Dosage: 30-60 mg/hr intra-arterially

Effectiveness
85%
Safety Score
50%
Clinical Trials
30
Participants
300

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
30-60 mg/hr intra-arterially
Time to Effect
Minutes-hours
Treatment Duration
24-72 hours
Evidence Quality
LOW
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$8,000
Side Effect Mgmt:$500
Total Annual:$8,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$11,467
Comparison vs Supportive Care Only (for NOMI)
Cost Difference
$-50,000/year
Less expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Papaverine (Intra-arterial) Outcomes

for Vascular Intestinal Disorders

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+75%
Common Side Effects
Hypotension
+5%
Cardiac arrhythmias
+2%
Local arterial complications
+3%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov